Form 8-K Adverum Biotechnologies, For: Apr 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RBC Capital Downgrades Adverum Biotechnologies (ADVM) to Sector Perform
April 29, 2021 6:18 AM EDTRBC Capital analyst Luca Issi downgraded Adverum Biotechnologies (NASDAQ: ADVM) from Outperform to Sector Perform with a price target of $6.00 (from $30.00).
The analyst comments "ADVM announced a serious adverse event of hypotony (decreased intraocular pressure), panuveitis and loss of vision in a DME... More
